Form 4: Xilio Therapeutics Director James Samuel Shannon Granted 31,000 Stock Options

Xilio Therapeutics, Inc. Director James Samuel Shannon was granted 31,000 stock options with an exercise price of $0.693, vesting over the next year.

Summary

• James Samuel Shannon, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options on June 11, 2025.
• The stock options have an exercise price of $0.693 per share.
• These options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date, subject to Mr. Shannon's continued service.
• The options are set to expire on June 10, 2035.
• Following this transaction, Mr. Shannon directly beneficially owns 31,000 stock options.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive for aligning interests and is a routine compensation event, indicating stability rather than a significant operational or financial breakthrough.

Positives

• The grant of stock options to a director helps align their long-term interests with those of the company's shareholders, incentivizing value creation.
• The exercise price of $0.693 provides a clear incentive for the director to contribute to the company's stock price appreciation.

Negatives

• No direct negatives are identified in this filing, as it reports a routine equity grant to an existing director.

Risks

• The vesting of the granted options is contingent upon the reporting person's continued service to Xilio Therapeutics, Inc. through the vesting date.

Future Outlook

The grant of long-term stock options to a director suggests an expectation of continued service and a belief in the company's future growth potential over the next decade, aligning the director's incentives with long-term shareholder value.

Management Comments

• N/A (Form 4 filings typically report transactions and do not include direct management comments or quotes).

Industry Context

This Form 4 filing reports a specific insider transaction, which is a routine disclosure for publicly traded companies and does not provide broader industry context or trends.

Comparison to Industry Standards

• N/A (This filing reports an individual insider transaction and does not contain data suitable for comparison to industry-wide financial or operational benchmarks).

Management Changes

Corporate Governance

Legal Proceedings

• N/A (This filing does not mention any legal proceedings or regulatory matters).

Related Party Transactions

• The grant of 31,000 stock options to James Samuel Shannon, a Director of Xilio Therapeutics, Inc., constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options to a director helps align the director's long-term interests with those of the shareholders, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The granted options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, SEC filing, stock options, insider transaction, director compensation, equity grant